Ozone therapy eradicates MRSA colonies and modulates immune response in human PBMCs
Background
Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant clinical challenge due to its limited susceptibility to conventional antibiotics and its ability to form biofilms, especially in deep tissue infections like osteomyelitis. Current standard-of-care often falls short, necessitating novel therapeutic strategies. Ozone (O3), a naturally occurring molecule, exhibits potent antimicrobial properties against a wide spectrum of microorganisms, including MRSA. Its efficacy has been demonstrated in both in vivo and in vitro settings, highlighting its potential as a valuable adjunctive therapy for managing resistant bacterial infections.
Study Design
Human peripheral blood mononuclear cells (PBMCs) from healthy donors were initially exposed to either heat-killed or O3-treated MRSA strains for 2 hours at 37 °C. Subsequently, these PBMCs were treated with 40 μg/mL O3 for an additional 24 hours to simulate ozone therapy. Researchers then employed a multidisciplinary approach, utilizing biochemical, molecular, and cell biology techniques to assess key parameters. These included cytokine release, antioxidant and pro-oxidant gene expression, reactive oxygen species (ROS) production, and redox-related biomarker levels.
Results
Ozone, at various concentrations ranging from 20-60 μg/mL, demonstrated a potent antibacterial effect against MRSA, falling within the established therapeutic range of 20-80 μg/mL. This efficacy resulted in the complete loss of bacterial colonies when tested in a medium devoid of antioxidants. Furthermore, the study revealed that ozone exerts significant immunomodulatory and antioxidant effects on PBMCs stimulated with MRSA. These beneficial effects were observed as early as 1 hour after stimulation and persisted for up to 48-72 hours, irrespective of whether the bacteria were inactivated by ozone or heat. The findings suggest a dual mechanism of action, directly targeting the pathogen while simultaneously enhancing host immune responses.
Ozone, at concentrations of 20-60 μg/mL within the therapeutic range, demonstrated a potent antibacterial effect against MRSA, leading to complete loss of bacterial colonies in the absence of antioxidants.
Key Findings
- Ozone (20-60 μg/mL) achieved complete eradication of MRSA colonies in vitro.
- Ozone demonstrated immunomodulatory effects on human PBMCs stimulated with MRSA.
- Antioxidant effects were observed in PBMCs exposed to ozone and MRSA.
- Immunomodulatory and antioxidant effects began within 1 hour and lasted 48-72 hours.
Why It Matters
Ozone shows significant promise as an adjunctive therapy for challenging bacterial infections like MRSA, potentially offering a novel approach beyond conventional antibiotics. This dual action—direct bactericidal effect and host immunomodulation—could be particularly beneficial in cases where antibiotic resistance is prevalent or in biofilm-associated infections. The observed persistence of immunomodulatory effects for up to 72 hours suggests a sustained therapeutic window. While currently an in vitro finding, this research supports further investigation into clinical protocols for topical or systemic ozone application, potentially improving outcomes in difficult-to-treat infections and reducing reliance on traditional antibiotics.
ozone
mrsa
antibacterial
immunomodulation
antioxidant
in-vitro